|
1
|
Niederau C, Lange S, Heintges T, Erhardt
A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W
and Häussinger D: Prognosis of chronic hepatitis C: results of a
large, prospective cohort study. Hepatology. 28:1687–1695. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedman SL: Liver fibrosis - from bench
to bedside. J Hepatol. 38(Suppl 1): S38–S53. 2003. View Article : Google Scholar
|
|
3
|
Cadranel JF, Rufat P and Degos F:
Practices of liver biopsy in France: results of a prospective
nationwide survey. For the Group of Epidemiology of the French
Association for the Study of the Liver (AFEF). Hepatology.
32:477–481. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poynard T, Ratziu V and Bedossa P:
Appropriateness of liver biopsy. Can J Gastroenterol. 14:543–548.
2000.PubMed/NCBI
|
|
5
|
He QY, Cheung YH, Leung SY, Yuen ST, Chu
KM and Chiu JF: Diverse proteomic alterations in gastric
adenocarcinoma. Proteomics. 4:3276–3287. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi Y, Chiu JF, Wang L, Kwong DL and He QY:
Comparative proteomic analysis of esophageal squamous cell
carcinoma. Proteomics. 5:2960–2971. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finehout EJ, Franck Z and Lee KH:
Complement protein isoforms in CSF as possible biomarkers for
neurodegenerative disease. Dis Markers. 21:93–101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanninen K, Goldsteins G, Auriola S,
Alafuzoff I and Koistinaho J: Glycosylation changes in Alzheimer’s
disease as revealed by a proteomic approach. Neurosci Lett.
367:235–240. 2004.
|
|
9
|
Zanusso G, Righetti PG, Ferrari S, Terrin
L, Farinazzo A, Cardone F, Pocchiari M, Rizzuto N and Monaco S:
Two-dimensional mapping of three phenotype-associated isoforms of
the prion protein in sporadic Creutzfeldt-Jakob disease.
Electrophoresis. 23:347–355. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He QY, Lau GK, Zhou Y, Yuen ST, Lin MC,
Kung HF and Chiu JF: Serum biomarkers of hepatitis B virus infected
liver inflammation: a proteomic study. Proteomics. 3:666–674. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steel LF, Shumpert D, Trotter M, Seeholzer
SH, Evans AA, London WT, Dwek R and Block TM: A strategy for the
comparative analysis of serum proteomes for the discovery of
biomarkers for hepatocellular carcinoma. Proteomics. 3:601–609.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burgess-Cassler A, Johansen JJ and
Kendrick NC: Two-dimensional gel analysis of serum apolipoprotein
A-I isoforms: preliminary analysis suggests altered ratios in
individuals with heart disease. Appl Theor Electrophor. 3:41–45.
1992.
|
|
13
|
Fuhrman MP, Charney P and Mueller CM:
Hepatic proteins and nutrition assessment. J Am Diet Assoc.
104:1258–1264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tong L, Baskaran G, Jones MB, Rhee JK and
Yarema KJ: Glycosylation changes as markers for the diagnosis and
treatment of human disease. Biotechnol Genet Eng Rev. 20:199–244.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gravel P, Walzer C, Aubry C, Balant LP,
Yersin B, Hochstrasser DF and Guimon J: New alterations of serum
glycoproteins in alcoholic and cirrhotic patients revealed by high
resolution two-dimensional gel electrophoresis. Biochem Biophys Res
Commun. 220:78–85. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garner B, Merry AH, Royle L, Harvey DJ,
Rudd PM and Thillet J: Structural elucidation of the N- and
O-glycans of human apolipoprotein(a): role of o-glycans in
conferring protease resistance. J Biol Chem. 276:22200–22208. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He Z, Aristoteli LP, Kritharides L and
Garner B: HPLC analysis of discrete haptoglobin isoform N-linked
oligosaccharides following 2D-PAGE isolation. Biochem Biophys Res
Commun. 343:496–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nelsestuen GL, Zhang Y, Martinez MB, Key
NS, Jilma B, Verneris M, Sinaiko A and Kasthuri RS: Plasma protein
profiling: unique and stable features of individuals. Proteomics.
5:4012–4024. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sahu A and Lambris JD: Structure and
biology of complement protein C3, a connecting link between innate
and acquired immunity. Immunol Rev. 180:35–48. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee IN, Chen CH, Sheu JC, Lee HS, Huang
GT, Chen DS, Yu CY, Wen CL, Lu FJ and Chow LP: Identification of
complement C3a as a candidate biomarker in human chronic hepatitis
C and HCV-related hepatocellular carcinoma using a proteomics
approach. Proteomics. 6:2865–2873. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gangadharan B, Antrobus R, Dwek RA and
Zitzmann N: Novel serum biomarker candidates for liver fibrosis in
hepatitis C patients. Clin Chem. 53:1792–1799. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Citarella F, Felici A, Brouwer M, Wagstaff
J, Fantoni A and Hack CE: Interleukin-6 downregulates factor XII
production by human hepatoma cell line (HepG2). Blood.
90:1501–1507. 1997.PubMed/NCBI
|
|
23
|
Imbert-Bismut F, Ratziu V, Pieroni L,
Charlotte F, Benhamou Y and Poynard T: Biochemical markers of liver
fibrosis in patients with hepatitis C virus infection: a
prospective study. Lancet. 357:1069–1075. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Myers RP, De Torres M, Imbert-Bismut F,
Ratziu V, Charlotte F and Poynard T: Biochemical markers of
fibrosis in patients with chronic hepatitis C: a comparison with
prothrombin time, platelet count, and age-platelet index. Dig Dis
Sci. 48:146–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rossi E, Adams L, Prins A, Bulsara M, de
Boer B, Garas G, MacQuillan G, Seers D and Jeffrey G: Validation of
the FibroTest biochemical markers score in assessing liver fibrosis
in hepatitis C patients. Clin Chem. 49:450–454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vergnes L, Baroukh N, Lehy T, Moizo L,
Bado A, Baralle M, Baralle FE, Zakin MM and Ochoa A: Human
apolipoprotein A-IV reduces gastric acid secretion and diminishes
ulcer formation in transgenic mice. FEBS Lett. 460:178–181. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quilliot D, Walters E, Guerci B, Fruchart
JC, Duriez P, Drouin P and Ziegler O: Effect of the inflammation,
chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV
concentration in type 1 diabetes mellitus and in diabetes secondary
to chronic pancreatitis. Metabolism. 50:1019–1024. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyata Y, Koga S and Ibayashi H:
Alterations in plasma levels of apolipoprotein A-IV in various
clinical entities. Gastroenterol Jpn. 21:479–485. 1986.PubMed/NCBI
|
|
29
|
Seishima M, Usui T, Naganawa S, Nishimura
M, Moriwaki H, Muto Y and Noma A: Reduction of intestinal apo A-IV
mRNA levels in the cirrhotic rat. J Gastroenterol Hepatol.
11:746–751. 1996. View Article : Google Scholar : PubMed/NCBI
|
